Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Sponsor: Tallac Therapeutics
Summary
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Official title: A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2022-06-28
Completion Date
2026-05-19
Last Updated
2024-08-16
Healthy Volunteers
No
Conditions
Interventions
TAC-001
TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
Locations (12)
University of Southern California (USC)
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
Sarah Cannon Research Institute (SCRI)- Denver
Denver, Colorado, United States
AdventHealth Cancer Institute
Orlando, Florida, United States
Sarah Cannon Research Institute (SCRI)- Florida Cancer Specialists and Research Institute, LLC
Orlando, Florida, United States
John Theurer Cancer Center
Hackensack, New Jersey, United States
Weill Cornell Medicine- NYU Clinical Cancer Center
New York, New York, United States
West Cancer Center & Research Institute
Germantown, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology
Irving, Texas, United States
NEXT Oncology- Virginia
Fairfax, Virginia, United States
Clinical Site
Nedlands, Western Australia, Australia